The REPLACE Registry for Cholbam® (Cholic Acid)

Study Summary

This is a prospective, observational, non-interventional patient registry study designed to document product safety and effectiveness outcomes for 10 years in patients treated with Cholbam, including those who have been using Cholbam for at least 30 days (existing users) and those who are first-time initiators of Cholbam.

Conditions

Bile Acid Synthesis Disorders

Interventions / Drugs

Cholbam

View on ClinicalTrials.gov ↗

Sponsor

MIRM

Mirum Pharmaceuticals

Liver Disease

D37/100

Study Details

Enrollment55 participants

Primary Completion—

Lead SponsorMirum Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:21:18.704737+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.